Fierce Pharma
Fierce Biotech
Fierce Healthcare
Fierce Life Sciences Events
Advertise
About Us
Biotech
Cell & Gene Therapy
Clinical Data
Venture Capital
Deals
Research
Medtech
Devices
Diagnostics
AI and Machine Learning
CRO
Special Reports
Trending
Biologics
Clinical Development
Ophthalmology
Cell & Gene Therapy
Drug Development
Small Molecule Research & Development
Fierce 50
Special Report
Awards Gala
Awards
Outsourcing Awards
Innovation Awards
Resources
Fierce Events
Industry Events
Webinars
Podcasts
Whitepapers
Survey
Events
Subscribe
Subscribe
Biotech
Cell & Gene Therapy
Clinical Data
Venture Capital
Deals
Research
Medtech
Devices
Diagnostics
AI and Machine Learning
CRO
Special Reports
Trending
Biologics
Clinical Development
Ophthalmology
Cell & Gene Therapy
Drug Development
Small Molecule Research & Development
Fierce 50
Special Report
Awards Gala
Awards
Outsourcing Awards
Innovation Awards
Resources
Fierce Events
Industry Events
Webinars
Podcasts
Whitepapers
Survey
Events
Subscribe
Fierce Pharma
Fierce Biotech
Fierce Healthcare
Fierce Life Sciences Events
Advertise
About Us
MiroBio
Biotech
Gilead scraps lead arthritis drug from $405M MiroBio buyout
Gilead has abandoned work on the lead rheumatoid arthritis drug from its $405 million buyout of MiroBio in the latest blow to the BTLA agonist field
James Waldron
May 29, 2026 7:18am
Gilead makes $405M buy to compete with Lilly's BTLA program
Aug 4, 2022 11:46am
Oxford Science Enterprises clinches £250M for new startups
Jul 18, 2022 11:26am
Chasing Lilly, MiroBio raises $97M for autoimmune checkpoint R&D
Jun 29, 2022 3:00am
Novartis loses cell, gene leader, digital exec—Chutes & Ladders
Sep 24, 2021 9:30am
Novartis veteran Barth takes the helm at MiroBio
Sep 21, 2021 6:30am
